Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 6/20 | 0.54 |
| ▸ | MAOB | P27338 | 6/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113630 | 0.80 | TP53 (0.75) | TP53MAPK1MAOAMAOBRXFP1 | |
| SCHEMBL25201811 | 0.71 | MAOA (1.00) | MAPK1MAOAMAOBRXFP1KMT2A | |
| SCHEMBL11604357 | 0.70 | CYP1A2 (0.51) | RXFP1KMT2AALDH1A1PKMMEN1 | |
| SCHEMBL25206902 | 0.66 | MAOB (1.00) | MAPK1MAOAMAOBRXFP1ALDH1A1 | |
| SCHEMBL3372363 | 0.66 | ALDH1A1 (0.60) | TP53MAPK1ALDH1A1NPSR1 | |
| SCHEMBL25204131 | 0.65 | MAOB (1.00) | MAOAMAOBRXFP1KMT2APKM | |
| SCHEMBL10477412 | 0.64 | ADORA2B (0.56) | MAPK1RXFP1KMT2AMEN1POLB | |
| SCHEMBL18832690 | 0.63 | PKM (0.51) | MAOAMAOBKMT2AALDH1A1PKM | |
| SCHEMBL21602500 | 0.63 | RXFP1 (0.79) | MAPK1MAOAMAOBRXFP1KMT2A | |
| SCHEMBL21602513 | 0.62 | RXFP1 (1.00) | MAPK1MAOAMAOBRXFP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | ACTELION PHARMACEUTICALS,LTD. (CH) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | HRH2, HRH1, HRH3 | TP53 3872/4885MAPK1 1024/4885MAOA 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.